Abdi İbrahim Adds North Macedonia to Its International Growth Journey

Abdi İbrahim, which has maintained its leadership in the Turkish pharmaceutical sector for 24 years, has added North Macedonia to the markets in which it operates as part of its international growth strategy. The company launched the new phase of its activities in the country with a launch event held in Skopje, attended by healthcare professionals, public representatives, business partners and industry stakeholders.

Continuing its international growth with 114 years of experience, Abdi İbrahim aims to strengthen its presence in North Macedonia through its product portfolio and organizational structure tailored to local healthcare needs, while expanding the geography in which it operates with its new structure in the country.

Abdi İbrahim operates in 21 countries

Abdi İbrahim currently operates in 21 countries through its own organizations and delivers products to more than 70 countries. Maintaining its international operations with approximately 6 thousand employees, the company supports its global growth not only with its production infrastructure in Türkiye but also with local manufacturing investments in different countries.

The company has facilities with an annual production capacity of 24 million units in Kazakhstan and 51 million units in Algeria. As part of its structuring in North Macedonia, Abdi İbrahim has established its local organization and is shaping its product portfolio in line with the country's healthcare needs.

A growth model focused on local needs

Abdi İbrahim International Markets Group President Köksal Ülgen drew attention to the importance of the structuring in North Macedonia within the company's international growth strategy.

Ülgen said, “Our 114 years of experience, our production and R&D strength, our competencies in biotechnology, and our sustainability approach are transforming Abdi İbrahim into a strong pharmaceutical company growing on an international scale today. With our structuring in North Macedonia, we are carrying this accumulated knowledge to a new geography.”

Noting that the healthcare needs and priorities of every market are different, Ülgen stated that they have established a local team in North Macedonia and shaped the product portfolio according to the country's needs.

Stating that they aim to create a reliable distribution structure by working closely with healthcare professionals and institutions, Ülgen said, “Our goal is to steadily grow our presence in North Macedonia while supporting patients' access to the treatment options they need, through a strong local organization.”

Will focus on five core therapeutic areas

Abdi İbrahim is shaping its product portfolio in North Macedonia in line with local healthcare needs and the goal of supporting patient access.

The company's current focus in the country includes five core areas:

- Respiratory system,

- Central nervous system,

- Cardiovascular diseases,

- Pain,

- Over-the-counter (OTC) products

Abdi İbrahim's activities in North Macedonia are planned to be developed in the coming period in line with four core priorities. In this context, the company aims to expand patients' access to treatment options, strengthen local organization and stakeholder collaborations, develop the product portfolio according to local needs, and establish a reliable distribution network.

The company also considers medical education, scientific exchange and collaboration efforts with healthcare professionals and institutions as important elements of its long-term activities in the country.

“We aim to be a reliable and long-term partner of the healthcare system”

Abdi İbrahim North Macedonia Country Manager Natasha Poposka stated in her assessment of the company's goals in the country that they are focused on local needs and collaborations.

Poposka said, “We aim to be a reliable and long-term partner of the healthcare system in North Macedonia. We focus on understanding local needs, working in close collaboration with healthcare professionals and institutions, and supporting patients' access to treatment through our scientific contribution. We believe that strong partnerships and mutual trust form the foundation of sustainable development.”

About Abdi İbrahim

Founded by pharmacist Abdi İbrahim Bey in 1912 at a pharmacy in İstanbul's Küçükmustafapaşa neighborhood, Abdi İbrahim has maintained its leadership in the Turkish pharmaceutical sector since 2002.

Working with more than 30 licensors worldwide, the company has a portfolio of 255 brands and more than 530 products, including its own developed products. Operating in 13 of the 16 main therapeutic areas according to the IQVIA classification, Abdi İbrahim operates with its own organizational structure in 21 countries including Türkiye and exports to more than 70 countries.

The company, which has approximately 6 thousand employees, has an R&D Center, a Chemical Products Manufacturing Facility, the AbdiBio biotechnological drug manufacturing facility, a Hormone Production Facility, a Sterile Ophthalmology and Sterile Inhalation Manufacturing Facility, and a Chemical, Oncology and Sterile Manufacturing Facility at its İstanbul Esenyurt Production Complex. Abdi İbrahim also has R&D centers and manufacturing facilities in Kazakhstan and Algeria.